- Home
- IFRX
IFRX
InflaRx N.V.
as 05-16-2025 3:37pm EST
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
| Founded: | 2007 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 65.8M | IPO Year: | 2017 |
| Target Price: | $8.50 | AVG Volume (30 days): | 262.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.82 - $2.81 | Next Earning Date: | 05-07-2025 |
| Revenue: | $140,242 | Revenue Growth: | 30.90% |
| Revenue Growth (this year): | 61.96% | Revenue Growth (next year): | 80.59% |
Latest InflaRx N.V. News
IFRX Breaking Stock News: Dive into IFRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)
GlobeNewswire
13 days ago
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
20 days ago
InflaRx to Report First Quarter 2025 Results on May 7, 2025
MT Newswires
21 days ago
Cantor Fitzgerald Initiates InflaRx at Overweight $10 Price Target
Insider Monkey
2 months ago
Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?
Zacks
2 months ago
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
GlobeNewswire
2 months ago
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
GlobeNewswire
2 months ago
InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
Compare IFRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IFRX InflaRx N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.